Abstract
AbstractStimulant drugs, transcranial magnetic stimulation, brain-computer interfaces, and even genetic modifications are all discussed as forms of potential cognitive enhancement. Cognitive enhancement can be conceived as a benefit-seeking strategy used by healthy individuals to enhance cognitive abilities such as learning, memory, attention, or vigilance. This phenomenon is hotly debated in the public, professional, and scientific literature. Many of the statements favoring cognitive enhancement (e.g., related to greater productivity and autonomy) or opposing it (e.g., related to health-risks and social expectations) rely on claims about human welfare and human flourishing. But with real-world evidence from the social and psychological sciences often missing to support (or invalidate) these claims, the debate about cognitive enhancement is stalled. In this paper, we describe a set of crucial debated questions about psychological and social aspects of cognitive enhancement (e.g., intrinsic motivation, well-being) and explain why they are of fundamental importance to address in the cognitive enhancement debate and in future research. We propose studies targeting social and psychological outcomes associated with cognitive enhancers (e.g., stigmatization, burnout, mental well-being, work motivation). We also voice a call for scientific evidence, inclusive of but not limited to biological health outcomes, to thoroughly assess the impact of enhancement. This evidence is needed to engage in empirically informed policymaking, as well as to promote the mental and physical health of users and non-users of enhancement.
Funder
Fonds de Recherche du Québec - Santé
John Templeton Foundation
Deutsche Forschungsgemeinschaft
Universität zu Köln
Publisher
Springer Science and Business Media LLC
Subject
Management of Technology and Innovation,Health Policy,Issues, ethics and legal aspects,Health (social science)
Reference97 articles.
1. Allen, A. L., & Strand, N. K. (2015). Cognitive enhancement and beyond: Recommendations from the bioethics commission. Trends in Cognitive Sciences, 19(10), 549–551.
2. Allen, B., & Harocopos, A. (2016). Non-prescribed buprenorphine in New York City: Motivations for use, practices of diversion, and experiences of stigma. Journal of Substance Abuse Treatment, 70, 81–86.
3. Battleday, R., & Brem, A. (2015). Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review. European Neuropsychopharmacology, 25(11), 1865–1881.
4. Baum, M., Sattler, S., & Reimann, M. (in press). Towards an understanding of how stress and resources affect the nonmedical use of prescription drugs for performance enhancement among employees. Current Psychology.
5. Bavelier, D., Savulescu, J., Fried, L. P., Friedmann, T., Lathan, C. E., Schürle, S., Beard, J.R. (2019). Rethinking human enhancement as collective welfarism. Nature Human Behaviour, 3(3), 204–206.
Cited by
33 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献